Clinical trial

Median Effective Dose of Cisatracurium for the Prevention of Fasciculation Caused by the Injection of Succinylcholine

Name
20230226
Description
Succinylcholine is currently the only depolarizing neuromuscular blocker widely used in anesthesia induction and is the drug of choice for rapid sequential anesthesia induction. However, with succinylcholine, varying degrees of muscle fibrillation and muscle pain occur. Intravenous injection of succinylcholine caused by myomuscular fibrillation can cause increased intragastric pressure, intraocular pressure and intracranial pressure, increased serum potassium and postoperative myalgia, increased the incidence of adverse events such as needle prolapse, extravasation of injected drugs, and reduced perioperative comfort of patients. Pretreatment with cisatracurium provides limited prevention of muscular fibrillation due to succinylcholine, but the choice of dose often depends on user experience, and there have been no previous studies of age-related doses of cisatracurium for the prevention of muscular fibrillation caused by succinylcholine, and its half-effective amount (ED50) has not been established. In this study, patients treated with elective general anesthesia surgery were the subjects, and in the process of general anesthesia induction, cis-atracurium was pretreated to evaluate the degree of inhibition of muscular fibrillation caused by succinylcholine, and half of the effective dose of cis-atracurium inhibition of muscular fibrillation caused by succinylcholine was calculated by sequential method.
Trial arms
Trial start
2023-02-01
Estimated PCD
2023-08-31
Trial end
2023-08-31
Status
Recruiting
Treatment
Cisatracurium
Advanced intravenous injection of cisatracurium before the succinylcholine injection
Arms:
Age range of 18 to 44 years olds, Age range of 45 to 59 years olds, Age range of 60 to 80 years olds
Size
90
Primary endpoint
The appearance of fasciculation Yes or No
an average of 2 minutes
The levels of fasciculation
an average of 2 minutes
Eligibility criteria
Inclusion Criteria: 1. Ages ranged from 18 to 80. 2. ASA # or # level. Exclusion Criteria: * Allergy or contraindication to cisatracurium or succinylcholine; * Associated with cardiovascular disease, diabetes, hyperkalemia, increased intraocular pressure, increased intracranial pressure, gastroesophageal reflux, difficult airway, malignant hyperthermia, neuromuscular disease Sick; * Take drugs that may affect neuromuscular function before surgery * Liver or kidney failure * Pregnancy
Protocol
{'studyType': 'INTERVENTIONAL', 'phases': ['NA'], 'designInfo': {'allocation': 'RANDOMIZED', 'interventionModel': 'PARALLEL', 'primaryPurpose': 'PREVENTION', 'maskingInfo': {'masking': 'NONE'}}, 'enrollmentInfo': {'count': 90, 'type': 'ESTIMATED'}}
Updated at
2023-03-09

1 organization

1 product

2 indications

Indication
Fasciculation
Indication
Suxamethonium